Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes
Launched by NOVO NORDISK A/S · Feb 6, 2008
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 1 or 2 diabetes for at least 3 months
- • Stabilised on current treatment with premixed human insulin for at least 4 weeks
- • Body mass index (BMI) between 18-40 kg/m2
- • HbA1c below 13.0%
- • Able and willing to perform self-blood glucose monitoring
- Exclusion Criteria:
- • The receipt of any investigational drug within the last three months prior to this trial
- • Has a history of drug abuse or alcohol dependence within the last 5 years
- • Active proliferative retinopathy requiring laser or surgical intervention within the last year
- • Recurrent major hypoglycaemia as judged by the Investigator
- • Known or suspected allergy to trial product or related product
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Shanghai, Shanghai, China
Beijing, Beijing, China
Shanghai, Shanghai, China
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials